Discover Nano· 2026Q1· Review
Nanomedicines based on renewable materials for sustainable drug delivery and biomedical imaging applications
- 0citations
- Q1SCImago
- 2026year
Short summary
This review critically evaluates nanomedicines made from renewable polymers, polysaccharides, proteins, and lipids for drug delivery and biomedical imaging, focusing on how material origin and properties affect performance and clinical readiness.
AI-generated from the title and abstract; the full text is not read.
Key points
- Nanomedicines are being developed using renewable materials like polymers, polysaccharides, proteins, and lipids.
- These materials offer sustainable, biodegradable, and biocompatible alternatives to fossil-based resources.
- The review compares different renewable material classes based on source consistency, biodegradability, imaging functionality, and regulatory maturity.
- Key translational barriers and evidence gaps hindering clinical readiness of renewable material-based nanomedicines are identified.
AI-generated from the title and abstract; the full text is not read.
Abstract
With the application of nanoscale materials, nanomedicine is redefining and improving the delivery of pharmaceuticals and molecular bioimaging probes, providing novel approaches to disease diagnosis, management, and treatment. As in many other fields, renewable materials are becoming increasingly important in nanomedicine because they offer sustainable alternatives to fossil-based resources and are often biodegradable and biocompatible. Additionally, these materials are replenishable in nature, and some can be derived or recovered from industrial and agro-industrial waste streams. In this review, we critically evaluate nanomedicines fabricated from renewable polymers, polysaccharides, proteins, and lipids for drug delivery and biomedical imaging, together with their physicochemical and biological characterization. Particular emphasis is placed on how material origin and physicochemical properties influence formulation performance and clinical readiness. Rather than considering renewable origin alone as an indicator of translational suitability, the major material classes are compared in terms of source consistency, biodegradability, imaging functionality, and regulatory maturity. Recent developments reported during 2020–2026 are discussed, with particular attention to the objectives and key findings of the developed nanomedicines. Additionally, their applications in the treatment of various diseases and in biomedical imaging are reviewed. The review also highlights key translational barriers, and evidence gaps that must be addressed to advance renewable material-based nanomedicines from proof-of-concept systems toward reproducible, scalable, and clinically relevant products. Graphic abstract
The authors' abstract, as published at the source. Discover Nano, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Biomaterials
BiomaterialsMaterials Science